Biotech Values

[ghmm]

I voted positive. But for the record I wasn't the one who voted ITMN for the first 5-bagger :).

I think it is a risky trial no doubt. My reasons for are similar to why I have stayed invested (my posts on the ITMN board talk about them). The Actimmune trial beening stopped early really makes this critical for the company. Had it gone to completion (and had mixed results) I think the company had a chance to cushion more (license another compound raise a bit more capital, etc.).

We'll find out soon enough.... or if it is like the original Actimmune Phase 3 or not